• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Quantum Computing (QUBT) Enters Pharma Research, Is The Upside Already Priced In?

    Simply Wall St·10/25/2026 07:25:06
    Listen to the news

    Quantum Computing's pharma collaboration as a potential inflection point

    Quantum Computing (QUBT) just moved its quantum optimization hardware into real pharmaceutical work through a new collaboration with INmune Bio, centered on identifying fresh indications for the XPro1595 therapy.

    The engagement focuses on combining QCi's Dirac-3S entropy quantum optimization machine with AI and conventional data analytics to sift through INmune Bio's pre-clinical and clinical datasets for new disease targets.

    Against this backdrop, Quantum Computing’s shares have pulled back sharply in recent months, with a 30 day share price return down 26.79% and year to date performance weaker. At the same time, the 3 year total shareholder return remains very large, suggesting long term investors have already experienced a powerful swing in sentiment.

    The fresh INmune Bio alliance and recent AUSA 2026 presentation arrive as the 7 day share price return of 3.14% contrasts with the 1 year total shareholder return decline of 57.76%. This hints that shorter term traders are reassessing both growth potential and execution risk around QUBT’s quantum hardware being applied in real world settings.

    Spot 38 AI small caps harnessing quantum, AI and advanced data analytics in ways similar to Quantum Computing’s push into real-world pharmaceutical research.

    Quantum Computing now trades far below the average analyst target, with a wide gap between recent price pressure and optimistic valuation models. Where does a reasonable fair value band actually fall once those expectations are stripped back to the cash flows and risks on the table?

    Most Popular Narrative: 64% Undervalued

    On the most followed narrative, Quantum Computing’s fair value sits at $18.33 versus a last close of $6.56. This sets a wide gap that investors need to justify with very ambitious operating outcomes.

    The move from prototype systems to planned volume manufacturing by the end of the decade, supported by over $1.5 billion of newly raised capital and a low liability balance, allows QCi to invest aggressively in automation, yield improvement and design reuse. These efforts should help reduce unit costs and support sustained improvement in gross margin and earnings power.

    See why 75 investors see Quantum Computing as 64% undervalued.

    Analysts in this framework are assuming revenue growth of roughly 283% a year and a profit margin near 0.7%, then discounting those future cash flows back at an 8.51% rate to arrive at that $18.33 figure.

    Those same assumptions imply earnings of $1.8 million by about 2029 and a very high future P/E multiple. This means a large part of the valuation rests on Quantum Computing scaling from today’s $9.824 million in revenue into a much bigger commercial base without losing pricing power.

    That is a tall order, so it can help to stress test the narrative by asking whether such rapid expansion, thin target margins and share count growth of 7% a year line up with your own expectations for customer adoption and competitive pressure in quantum hardware, photonics and AI acceleration.

    Result: Fair Value of $18.33 (UNDERVALUED)

    Still, the narrative can crack if Quantum Computing fails to turn small, contract driven revenue into repeatable products, or if rising operating costs outpace that hoped for expansion.

    Find out about the key risks to this Quantum Computing narrative.

    Next Steps

    If the mix of optimism and caution around Quantum Computing feels hard to evaluate, consider acting promptly to compare the numbers with your own thesis. To understand what is driving the current upbeat sentiment, review the 1 key reward

    Looking for more Quantum Computing style investment ideas?

    If Quantum Computing has sharpened your curiosity, you can widen your watchlist now with a few focused screeners that highlight different ways of thinking about opportunity and risk.